United Therapeutics CEO Rothblatt sells $5.16m in shares

Martine A. Rothblatt, Chairman and CEO of United Therapeutics Corp (UTHR), sold 9,500 shares on October 19, 2026, for a total of $5.16 million. The shares were sold at prices between $534.75 and $556.88, while the stock is currently trading at $554.23, up 25% year-over-year. This action came following the exercise of 9,500 stock options at $117.76 per share, totaling $1.12 million.

Both transactions were made under a pre-established 10b5-1 trading plan, which Ms. Rothblatt implemented on November 7, 2025, and will continue until either 1,734,410 stock options are exercised or December 31, 2026, whichever occurs first. Ms. Rothblatt indirectly holds approximately 400,000 shares through family trusts, while she directly owns 40,513 shares.

The stock options exercised were part of a grant that vested in three equal installments over the years 2021, 2022, and 2023. Following the sale, United Therapeutics reported Q2 results, falling short of revenue expectations, leading to a price target adjustment from $613 to $559 by BofA Securities. Additionally, a $380.7 million settlement with Liquidia Technologies has been reached, resolving their legal dispute and prompting analyst upgrades.